Home » Stocks » MNTA

Momenta Pharmaceuticals, Inc. (MNTA)

Sep 30, 2020 - MNTA was delisted after being acquired by JNJ
Stock Price: $52.48 USD 0.00 (0.00%)
Updated Oct 1, 2020 4:00 PM EDT
Market Cap 6.24B
Revenue (ttm) 30.07M
Net Income (ttm) -227.83M
Shares Out 117.87M
EPS (ttm) -2.09
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day Oct 1, 2020
Last Price $52.48
Previous Close $52.48
Change ($) 0.00
Change (%) 0.00%
Day's Open -
Day's Range 52.46 - 52.53
Day's Volume 0
52-Week Range 12.21 - 52.53

News

Hide News
GlobeNewsWire - 5 months ago

CAMBRIDGE, Mass., Oct. 01, 2020 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA, “Momenta” or the “Company”), a biotechnology company focused on discovering and developing nove...

Investopedia - 5 months ago

These are the pharmaceutical stocks with the best value, fastest growth, and most momentum for Q4 2020.

Other stocks mentioned: AZN, BIIB, NLTX, PRGO, RLMD, SNY, SUPN, TAK
GlobeNewsWire - 5 months ago

CAMBRIDGE, Mass., Sept. 15, 2020 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA, “Momenta” or the “Company”), a biotechnology company focused on discovering and developing...

Zacks Investment Research - 5 months ago

Momenta (MNTA) reported earnings 30 days ago. What's next for the stock?

Newsfile Corp - 6 months ago

New York, New York--(Newsfile Corp. - August 31, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:To view an enhanced version of this graphic, please visit:https://orde...

InvestorPlace - 6 months ago

Momenta Pharmaceuticals stock was thrust into the financial headlines and might look tempting, but don't forget that price is king. The post Buyout Excitement Is Already Priced Into Momenta Ph...

Seeking Alpha - 6 months ago

Johnson & Johnson has increased its dividend for 58 years in a row (a dividend king) and presently has a yield of 2.7%, which is above average.

Other stocks mentioned: JNJ
The Dog of Wall Street - 6 months ago

Johnson & Johnson to enroll 60,000 participants in the late-stage trial for its COVID-19 vaccine.

Other stocks mentioned: JNJ
Benzinga - 6 months ago

Johnson & Johnson (NYSE: JNJ) is borrowing $7.5 billion in bonds to help fund its purchase of Momenta Pharmaceuticals, Inc (NASDAQ: MNTA) as a series of companies tap the debt market to financ...

Other stocks mentioned: JNJ
Newsfile Corp - 6 months ago

New York, New York--(Newsfile Corp. - August 20, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:To: All Persons or Entities who purchased Momenta Pharmaceuticals, Inc.

Zacks Investment Research - 6 months ago

J&J (JNJ) offers to buy Momenta, which focuses on the development of novel drugs to treat rare, immune-mediated disorders.

Other stocks mentioned: JNJ
Forbes - 6 months ago

The stock price of Momenta Pharmaceuticals, a pharmaceutical company best known for its immunology therapies, has rallied around 26% over recent weeks (vs. about a 50% gain in the S&P 500) to ...

Other stocks mentioned: JNJ
PRNewsWire - 6 months ago

NEW YORK, Aug. 19, 2020 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Momenta Pharmaceuticals, Inc.

The Motley Fool - 6 months ago

The Fed spoiled the party for the stock market.

Other stocks mentioned: BMRN
InvestorPlace - 6 months ago

Momenta Pharmaceuticals (MNTA) news for Wednesday includes a deal with Johnson & Johnson (JNJ) sending MNTA stock rocketing higher.

Other stocks mentioned: JNJ
PRNewsWire - 6 months ago

NEW YORK, Aug. 19, 2020 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in Ne...

The Motley Fool - 6 months ago

A healthcare titan is acquiring the biotech in a $6.5 billion deal.

Other stocks mentioned: JNJ
The Motley Fool - 6 months ago

The company is paying a big premium to expand its autoimmune disease treatment footprint.

Other stocks mentioned: JNJ
Investors Business Daily - 6 months ago

Johnson & Johnson will buy Momenta Pharmaceuticals for $6.5 billion to broaden its reach in treating autoimmune and rare diseases. The post Johnson & Johnson To Acquire Momenta Pharmaceutical...

Other stocks mentioned: JNJ
PRNewsWire - 6 months ago

SAN DIEGO, Aug. 19, 2020 /PRNewswire/ -- Shareholder rights law firm Johnson Fistel, LLP has launched an investigation into whether the board members of Momenta Pharmaceuticals, Inc.

CNBC Television - 6 months ago

Johnson & Johnson to buy Momenta for about $6.5 billion

Johnson & Johnson said on Wednesday it would buy Momenta Pharmaceuticals for about $6.5 billion in cash to expand into the area of autoimmune disease treatments.

Other stocks mentioned: JNJ
Market Watch - 6 months ago

Shares of Momenta Pharmaceuticals Inc. MNTA, +5.04% rocketed 69% into record territory in premarket trading Wednesday, after the biotechnology company announced an agreement to be acquired by ...

Other stocks mentioned: JNJ
Reuters - 6 months ago

Johnson & Johnson said on Wednesday it would buy Momenta Pharmaceuticals Inc for about $6.5 billion in cash to expand into the area of autoimmune disease treatments.

Other stocks mentioned: JNJ
GlobeNewsWire - 6 months ago

CAMBRIDGE, Mass., Aug. 19, 2020 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA, “Momenta” or the “Company”), a biotechnology company focused on discovering and developing no...

PRNewsWire - 6 months ago

NEW BRUNSWICK, N.J., Aug. 19, 2020 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) today announced it has entered into a definitive agreement to acquire Momenta Pharmaceuticals, Inc.

Other stocks mentioned: JNJ
The Motley Fool - 6 months ago

No news is apparently bad news.

Seeking Alpha - 6 months ago

Momenta Pharmaceuticals, Inc. (MNTA) CEO Craig Wheeler on Q2 2020 Results - Earnings Call Transcript

Zacks Investment Research - 6 months ago

Momenta (MNTA) delivered earnings and revenue surprises of -14.29% and 13.15%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Benzinga - 6 months ago

Shares of Momenta Pharmaceuticals (NASDAQ:MNTA) rose 1% after the company reported Q2 results.

GlobeNewsWire - 6 months ago

-- Interim Phase 2 Vivacity-MG results met primary endpoints, demonstrating nipocalimab was well-tolerated and achieved rapid and durable responses with significant correlation (p

GlobeNewsWire - 7 months ago

CAMBRIDGE, Mass., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA), a biotechnology company focused on discovering and developing novel biologic therapeutics to...

Zacks Investment Research - 7 months ago

Momenta (MNTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlobeNewsWire - 7 months ago

CAMBRIDGE, Mass., July 28, 2020 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA) today announced that its novel drug candidate, nipocalimab, has received rare pediatric dis...

Zacks Investment Research - 8 months ago

Top Ranked Momentum Stocks to Buy for July 6th

Other stocks mentioned: PRPL, ZS
Zacks Investment Research - 8 months ago

Momenta (MNTA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Zacks Investment Research - 8 months ago

Despite market's roller-coaster ride, a handful of momentum stocks with a favorable Zacks Rank have provided double-digit returns so far in June.

Other stocks mentioned: CLW, CMC, DOMO, VRAY
Zacks Investment Research - 8 months ago

As of late, it has definitely been a great time to be an investor in Momenta Pharmaceuticals, Inc. (MNTA).

Zacks Investment Research - 8 months ago

Momenta (MNTA) stock up on the announcement of positive data from a mid-stage study on nipocalimab for the indication of gMG.

The Motley Fool - 8 months ago

Positive phase 2 clinical trial data puts the biotech's lead drug candidate on a good path forward.

GlobeNewsWire - 8 months ago

- Trial met primary endpoint with a strong relationship between Immunoglobulin G (IgG) reduction and MG-ADL clinical benefit (p

Zacks Investment Research - 8 months ago

Momenta (MNTA) reported earnings 30 days ago. What's next for the stock?

The Motley Fool - 9 months ago

Here’s why this drugmaker targeting autoimmune conditions and rare diseases is a solid buy.

Seeking Alpha - 9 months ago

Momenta Pharmaceuticals, Inc. (MNTA) CEO Craig Wheeler on Q1 2020 Results - Earnings Call Transcript

Zacks Investment Research - 10 months ago

Momenta (MNTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlobeNewsWire - 11 months ago

CAMBRIDGE, Mass., April 02, 2020 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA), a biotechnology company focused on discovering and developing novel biologic therapeutics...

Zacks Investment Research - 11 months ago

Momenta (MNTA) reported earnings 30 days ago. What's next for the stock?

The Motley Fool - 11 months ago

An overall market rebound and a presidential press conference carried several biotech and pharmaceutical stocks markedly higher.

Other stocks mentioned: BIIB, BMRN, EBS, MYL, NVAX
The Motley Fool - 1 year ago

Investors ran back into the stock after one of the worst weeks in market history. Will it prove sustainable?

Zacks Investment Research - 1 year ago

Momenta (MNTA) reports mixed Q4 results, with a wider-than-expected loss and revenues beating the same.

Seeking Alpha - 1 year ago

Momenta Pharmaceuticals, Inc. (MNTA) CEO Craig Wheeler on Q4 2019 Results - Earnings Call Transcript

About MNTA

Momenta Pharmaceuticals, a biotechnology company, focuses on the discovery and development of novel biologic therapies for the treatment of rare immune-mediated diseases in the United States. Its novel therapeutic programs include M281, a fully-human anti-neonatal Fc receptor (FcRn), aglycosylated immunoglobulin G (IgG1), and monoclonal antibody to reduce circulating IgG antibodies by blocking endogenous IgG recycling via FcRn; M230, a recombinant trivalent human IgG1 Fc multimer containing three IgG Fc regions joined to maximize activity; and ... [Read more...]

Industry
Drug Manufacturers—Specialty & Generic
IPO Date
Jun 22, 2004
CEO
Craig A. Wheeler
Employees
118
Stock Exchange
NASDAQ
Ticker Symbol
MNTA
Full Company Profile

Financial Performance

In 2019, MNTA's revenue was $23.87 million, a decrease of -68.42% compared to the previous year's $75.59 million. Losses were -$290.06 million, 64.7% more than in 2018.

Financial Statements